Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA).
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CZP-SPEED; SPEED
- Sponsors UCB
- 10 Jun 2017 Biomarkers information updated
- 10 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Apr 2014 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov.